ArticleMicroorganisms2025
Improved Natamycin Production in
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction of a library of gene expression elements in industrialSynthetic and systems biotechnology · 2026Article
- Abundant organic nitrogen enhances natamycin biosynthesis by increasing NAD(P) metabolic pathway activity inFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Natamycin is a polyene macrocyclic antibiotic extensively used in food, medical, and agricultural industries. However, its high production cost and low synthetic efficiency fail to meet the growing market demand. Therefore, enhancing the production of natamycin-producing strains is crucial for achieving its industrial-scale production. This study systematically evaluated 16 mutagenesis methods and identified atmospheric and room temperature plasma mutagenesis combined with 2-deoxyglucose tolerance screening as the optimal strategy for enhancing natamycin production. A high-yield mutant strain, AG-2, was obtained, achieving an 80% increase in natamycin production (1.53 g/L) compared to the original strain. Metabolic analysis revealed that glycolysis and the pentose phosphate pathway were enhanced in AG-2, while the tricarboxylic acid cycle was weakened, significantly increasing the supply of precursors such as acetyl-CoA, methylmalonyl-CoA, and the reducing power of NADPH. Additionally, overexpression of the nitrogen metabolism regulatory gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.